FILE PHOTO: An ampule of remdesivir is pictured during a news conference
The government said on Tuesday it has approved Gilead Sciences Inc’s antiviral drug remdesivir for emergency use in treating COVID-19 patients.
Remdesivir is the first drug to show improvement in COVID-19 patients in formal clinical trials. It was granted emergency use authorization by the U.S. Food and Drug Administration (FDA) last month and has received approval by Japanese health regulators.
“(Remdesivir) approved on June 1 under emergency use with condition for five dose administration,” the Drugs Controller General of India said in an email statement.
The drugmaker did not immediately respond to an email seeking further details.
As of Tuesday, India has 198,706 cases of coronavirus and has recorded 5,598 deaths, Health Ministry data showed.
Gilead Sciences had on Monday reported that remdesivir showed modest benefit in patients with moderate COVID-19 given a five-day course, while those who received it for 10 days in the study did not fare as well.
European and South Korean authorities are also looking at remdesivir, with South Korean health authorities last Friday saying they would request imports of the drug. Gilead is yet to gain regulatory approval in either market.
For nine of the last ten years, the most searches were for why Apple products and Evian water are so…
Almost half the world is voting in national elections this year and AI is the elephant in the room. There…
When 65 Indian construction workers landed in Israel on April 2 to start jobs once taken by Palestinians, they were…
Chhattisgarh-based environmental activist Alok Shukla was conferred the prestigious Goldman Environmental Prize for leading a community campaign to protect the…
On Tuesday, 30 April, the Congress accused PM Narendra Modi of ignoring the plight of farmers in Marathwada and also…
Widespread joblessness explains why Punjab’s migrants resort to desperate means to reach their final destinations. Dunki in Punjabi means to hop,…
This website uses cookies.